Drug Profile


Alternative Names: 1 alpha-hydroxyergocalciferol; 1-alpha-D2; 1-alpha-Hydroxyvitamin D2; GZ-427397; Hectorol; TSA 870

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Wisconsin at Milwaukee
  • Developer Genzyme Corporation; Sanofi Genzyme
  • Class Calcium regulators; Ergocalciferols; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperparathyroidism
  • Discontinued Breast cancer; Colorectal cancer; Plaque psoriasis; Postmenopausal osteoporosis; Prostate cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Dec 2016 Phase-III clinical trials in Hyperparathyroidism (In children, In adolescents) in USA (PO) (NCT02859896)
  • 04 Aug 2016 Sanofi plans a phase III trial for Secondary hyperparathyroidism (In children, In adolescents) in USA (NCT02859896)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top